Latest filings (excl ownership)
POS AM
Prospectus update (post-effective amendment)
18 Apr 24
POS AM
Prospectus update (post-effective amendment)
12 Apr 24
10-K
2023 FY
Annual report
12 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Entry into a Material Definitive Agreement
30 Oct 23
8-K
Regulation FD Disclosure
23 Aug 23
10-Q
2023 Q2
Quarterly report
18 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
Entry into a Material Definitive Agreement
13 Jul 23
D
$5.00 mm in debt / options / securities to be acquired, 15 investors
13 Jul 23
10-Q
2023 Q1
Quarterly report
19 May 23
8-K
Amendments to Articles of Incorporation or Bylaws
19 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
424B3
Prospectus supplement
2 May 23
EFFECT
Notice of effectiveness
26 Apr 23
POS AM
Prospectus update (post-effective amendment)
19 Apr 23
10-K/A
2022 FY
Annual report (amended)
19 Apr 23
POS AM
Prospectus update (post-effective amendment)
14 Apr 23
10-K
2022 FY
Annual report
14 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
8-K
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
13 Mar 23
8-K
Departure of Directors or Certain Officers
2 Mar 23
8-K
Oncotelic Issues Year End Message to Shareholders
3 Jan 23
8-K
Regulation FD Disclosure
20 Dec 22
10-Q
2022 Q3
Quarterly report
18 Nov 22
NT 10-Q
Notice of late quarterly filing
14 Nov 22
10-Q
2022 Q2
Quarterly report
22 Aug 22
NT 10-Q
Notice of late quarterly filing
15 Aug 22
8-K
Regulation FD Disclosure
15 Jul 22
8-K
Entry into a Material Definitive Agreement
27 Jun 22
8-K
Regulation FD Disclosure
22 Jun 22
8-K
Entry into a Material Definitive Agreement
3 Jun 22
10-Q
2022 Q1
Quarterly report
23 May 22
NT 10-Q
Notice of late quarterly filing
16 May 22
424B3
Prospectus supplement
11 May 22
8-K
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer
6 May 22
EFFECT
Notice of effectiveness
6 May 22
POS AM
Prospectus update (post-effective amendment)
26 Apr 22
Latest ownership filings
4
Vuong Trieu
30 Jun 23
4
Vuong Trieu
20 Jun 23
4
Vuong Trieu
16 Jun 23
4
Vuong Trieu
31 May 23
4
Vuong Trieu
2 May 23
4
Vuong Trieu
7 Dec 22
4
Vuong Trieu
25 Nov 22
4
Vuong Trieu
28 Sep 22
4
Vuong Trieu
29 Aug 22
4
Vuong Trieu
8 Sep 21
4
ANTHONY E MAIDA III
8 Sep 21
4
STEVEN W KING
8 Sep 21
4
Saran Saund
8 Sep 21
4
ANTHONY E MAIDA III
16 Jul 21
4
Vuong Trieu
16 Jul 21
4
STEVEN W KING
16 Jul 21
4
Amit B. Shah
16 Jul 21
4
David Diamond
16 Jul 21
4
Saran Saund
16 Jul 21
4
Amit B. Shah
24 Nov 20
4
Chulho Park
23 Nov 20
4
Vuong Trieu
23 Nov 20
3
ANTHONY E MAIDA III
21 May 20
3
STEVEN W KING
21 May 20
4
Vuong Trieu
27 Mar 20
3
David Diamond
10 Feb 20
SC 13D
Mateon Therapeutics Inc
3 May 19
3
Vuong Trieu
2 May 19
3
Fatih Uckun
2 May 19
3
Chao Hsiao
2 May 19
3
Larn Hwang
2 May 19
3
Chulho Park
2 May 19
SC 13D
Mateon Therapeutics Inc
2 May 19
SC 13D
Mateon Therapeutics Inc
2 May 19
SC 13D
Mateon Therapeutics Inc
2 May 19
SC 13D
Mateon Therapeutics Inc
2 May 19
SC 13G/A
Mateon Therapeutics Inc
2 Jan 19
4
William D Schwieterman
22 Jun 18
4
BOBBY W. JR., PHD. SANDAGE
22 Jun 18
4
Donald Rogers Reynolds
22 Jun 18